Laurent Fischer
CEO, Pres, Dir
Adverum Biotechnologies, Inc.
ADVM·NASDAQ
MODERATE
59
The Alpha Score is an informational signal based on public SEC fillings. It is not investment advice.
CEOJOURNAL SIGNAL SUMMARY·GENERATED FROM PUBLIC SEC FILINGS
Laurent Fischer made an open-market purchase of Adverum Biotechnologies, Inc. on 2025-12-05, investing approximately $553,917. This is a CEOJournal signal summary placeholder — full narrative pending Claude Haiku enrichment.
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
Score Components
COMPOSITE ALPHA SCORE
59
Score calculated from open-market purchases only; 10b5-1 preplanned trades excluded; not investment advice.
OPPORTUNISM
Proxy from ownership-change magnitude. Real Opportunism signal will use %52W proximity once price data is in pipeline.
CONVICTION
Log-scaled from trade size. Real Conviction signal will use trade $ ÷ total compensation once DEF 14A data is in pipeline.
PATTERN
Placeholder — 90-day qualifying buy count requires historical Form 4 scrapes (Phase 2).
CLUSTER
Count of other insiders buying the same ticker in our current dataset window.
TRACK RECORD
Placeholder — executive tenure × prior buy P&L requires historical price tracking (Phase 2).
FORM 4 TRANSACTION HISTORYSOURCE: SEC EDGAR
| DATE | TRANSACTION TYPE | CODE | SHARES | PRICE | TOTAL VALUE | 10b5-1 | SCORE |
|---|---|---|---|---|---|---|---|
| Dec 05, 2025 | Open-Market Purchase | P | 128,699 | $4.30 | $553,917 | N/A | 59 |
Data sourced from SEC EDGAR Form 4 filings, updated within 24 hours.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
EXECUTIVE PROFILE
Laurent Fischer
CEO, Pres, Dir
Laurent Fischer, M.D. has served as the chief executive officer of Adverum Biotechnologies, Inc. since June 2020 and as president since June 2021. He was the interim chief medical officer from October 2021 to February 2022. Prior to joining Adverum, Dr. Fischer was senior vice president and head of the liver therapeutic area at Allergan PLC from November 2016 to June 2020, and he served as CEO of Tobira Therapeutics until its acquisition by Allergan in November 2016.
EDUCATION
- University of Geneva (undergraduate degree)
- Geneva Medical School, Switzerland (M.D.)
BOARD SEATS
- Mirum Pharmaceuticals, Inc · Board Member
- atai Life Sciences, N.V. · Board Member
- Teal Omics · Chairman
- Lycia Therapeutics · Board Member
- CTIC Biopharma · Chairman (previously)
COMPENSATION & OWNERSHIP ·SOURCE: DEF 14A PROXY
ANNUAL BASE SALARY
—
TOTAL COMPENSATION
$2,839,252
SHARES HELD
201,513
EST. HOLDINGS VALUE
—
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
RELATED SIGNALS